Immune monitoring using mRNA-transfected dendritic cells
Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Standard
Immune monitoring using mRNA-transfected dendritic cells. / Borch, Troels Holz; Svane, Inge Marie; Met, Özcan.
Synthetic mRNA: Production, Introduction Into Cells, and Physiological Consequences. Bind 1428 Humana Press, 2016. s. 245-259 (Methods in Molecular Biology, Bind 1428).Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - CHAP
T1 - Immune monitoring using mRNA-transfected dendritic cells
AU - Borch, Troels Holz
AU - Svane, Inge Marie
AU - Met, Özcan
PY - 2016
Y1 - 2016
N2 - Dendritic cells are known to be the most potent antigen presenting cell in the immune system and are used as cellular adjuvants in therapeutic anticancer vaccines using various tumor-associated antigens or their derivatives. One way of loading antigen into the dendritic cells is by mRNA electroporation, ensuring presentation of antigen through major histocompatibility complex I and potentially activating T cells, enabling them to kill the tumor cells. Despite extensive research in the field, only one dendritic cell-based vaccine has been approved. There is therefore a great need to elucidate and understand the immunological impact of dendritic cell vaccination in order to improve clinical benefit. In this chapter, we describe a method for performing immune monitoring using peripheral blood mononuclear cells and autologous dendritic cells transfected with tumor-associated antigen-encoding mRNA.
AB - Dendritic cells are known to be the most potent antigen presenting cell in the immune system and are used as cellular adjuvants in therapeutic anticancer vaccines using various tumor-associated antigens or their derivatives. One way of loading antigen into the dendritic cells is by mRNA electroporation, ensuring presentation of antigen through major histocompatibility complex I and potentially activating T cells, enabling them to kill the tumor cells. Despite extensive research in the field, only one dendritic cell-based vaccine has been approved. There is therefore a great need to elucidate and understand the immunological impact of dendritic cell vaccination in order to improve clinical benefit. In this chapter, we describe a method for performing immune monitoring using peripheral blood mononuclear cells and autologous dendritic cells transfected with tumor-associated antigen-encoding mRNA.
KW - Cancer immunotherapy
KW - Dendritic cell
KW - Electroporation
KW - Immune monitoring
KW - mRNA transfection
KW - Vaccination
U2 - 10.1007/978-1-4939-3625-0_16
DO - 10.1007/978-1-4939-3625-0_16
M3 - Book chapter
C2 - 27236804
AN - SCOPUS:84988860683
SN - 978-1-4939-3623-6
VL - 1428
T3 - Methods in Molecular Biology
SP - 245
EP - 259
BT - Synthetic mRNA
PB - Humana Press
ER -
ID: 176375911